◼ Archived
Business
Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail
Novartis faces a multi-billion dollar financial hit from clinical trial setbacks yet maintains financial guidance.
2 trends tracked about this subject — the full history, oldest to newest below.
Novartis faces a multi-billion dollar financial hit from clinical trial setbacks yet maintains financial guidance.
A major Novartis shareholder is demanding a board overhaul following a series of costly drug trial setbacks and strategic failures.